FLAURA2 总生存更新：奥希替尼 + 铂/培美一线
类型: III期临床试验 / 总生存更新 发表日期: 2025-10-17 入库日期: 2026-05-21 来源: PubMed / New England Journal of Medicine 标签: EGFR L858R, 奥希替尼, 铂类, 培美曲塞, FLAURA2, 总生存
Citation
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine. 2026. PMID: 41104938. DOI: 10.1056/NEJMoa2510308
Why it matters for mom
The CCL already includes the primary FLAURA2 evidence. This update matters because mom has actually lived through the strategy at issue: osimertinib plus platinum/pemetrexed-style chemotherapy in EGFR L858R metastatic NSCLC.
Practical takeaways
- This is the key evidence family members can use to understand why doctors may have chosen an aggressive osimertinib + chemotherapy strategy.
- Applicability depends on timing: FLAURA2 is first-line untreated advanced disease, while mom has later maintenance/rechallenge phases.
- Toxicity is central for mom because she has had marrow suppression and repeated chemotherapy exposure.
Questions for doctors
- Given her current marrow reserve, is continuing platinum/pemetrexed still net-beneficial?
- Is there a planned maximum number of platinum re-challenge cycles?
- If systemic control plateaus, should next steps be local therapy, repeat biopsy/NGS, antibody therapy, ADC trial, or treatment break?